Sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Call for patient/clinician input closed:
Manufacturer Requested Reimbursement Criteria1:
As an add-on maintenance treatment in patients aged 6 to <12 years with severe asthma with a type 2 or eosinophilic phenotype characterized by: • Symptoms that are not controlled despite optimal treatment, defined by the daily use of a medium or high dose ICS + 1 controller medication or high-dose ICS alone. • EOS ≥ 150 or FeNO ≥ 20 or allergy driven asthma. • Uncontrolled asthma having at least one severe exacerbation, defined by having experienced one or more hospitalization/emergency care visit OR treatment with a systemic corticosteroid (SCS, oral, or parenteral) in the past 12 months. • A baseline assessment of asthma symptom control using a validated asthma control questionnaire must be completed prior to initiation of dupilumab treatment.
As an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.
Date NOC Issued:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.